Navigation Links
Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
Date:7/23/2008

se in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule called Trp-p8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties surrounding the efficacy of PROVENGE to treat men suffering from prostate cancer, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials for PROVENGE will not support approval for a biologics license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a biologics license has been applied, the risk that the results of a clinical trial for PROVENGE or other product may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of PROVENGE, our dependence on the efforts of third pa
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
4. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
5. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
8. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
9. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
10. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
11. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014  Allakos Inc. ... $10 million investment from current investors to fund ... financing was completed following achievement of a key, ... program, and represents an extension of the company,s ... December 2012. With this additional financing, Allakos has ...
(Date:9/29/2014)... SAN DIEGO , 29 septembre 2014 ... Daiichi Sankyo) (TSE : 4568) et Ambit Biosciences (NASDAQ : ... accord de fusion définitif en vertu duquel Daiichi ... ordinaires en circulation d,Ambit Biosciences à 15 dollars ... offre publique d,achat qui sera suivie d,une fusion ...
(Date:9/29/2014)... -- BioMed Realty Trust, Inc. (NYSE: BMR ) ... approximately 200,000 square feet for 12 years with Baxter ... 650 East Kendall Street in Cambridge, Massachusetts ... a joint venture with Prudential Real Estate Investors. Baxter ... and development (R&D) center at the site for its ...
Breaking Medicine Technology:Allakos Inc. Raises Additional $10 Million to Expand its Portfolio and Fund Development of an Additional Antibody for Allergic and Inflammatory Diseases 2Allakos Inc. Raises Additional $10 Million to Expand its Portfolio and Fund Development of an Additional Antibody for Allergic and Inflammatory Diseases 3Allakos Inc. Raises Additional $10 Million to Expand its Portfolio and Fund Development of an Additional Antibody for Allergic and Inflammatory Diseases 4Daiichi Sankyo va acquérir Ambit Biosciences 2Daiichi Sankyo va acquérir Ambit Biosciences 3Daiichi Sankyo va acquérir Ambit Biosciences 4Daiichi Sankyo va acquérir Ambit Biosciences 5Daiichi Sankyo va acquérir Ambit Biosciences 6Daiichi Sankyo va acquérir Ambit Biosciences 7Daiichi Sankyo va acquérir Ambit Biosciences 8Daiichi Sankyo va acquérir Ambit Biosciences 9BioMed Realty Trust Signs A New 12-Year Lease Establishing New Innovation And R&D Center In Kendall Square In Cambridge, Massachusetts 2BioMed Realty Trust Signs A New 12-Year Lease Establishing New Innovation And R&D Center In Kendall Square In Cambridge, Massachusetts 3
... Aging Now has been selected by the editors ... fastest-growing private companies. Stop Aging Now , a ... vitamins and supplements. (Logo:   http://photos.prnewswire.com/prnh/20100817/INC5000LOGO ) ... Stop Aging Now was placed in the top ...
... Orthocare Innovations has been honored with the 2010 da ... most innovative technologies for people with disabilities. Orthocare received ... Compas™ is a first-of-its-kind device that lets people with ... to improve the alignment of their prosthesis. The system ...
Cached Medicine Technology:Stop Aging Now Named to Prestigious Inc. 5000 List 2Orthocare Innovations Wins da Vinci Award for Compas™ Computerized Prosthesis Alignment System 2Orthocare Innovations Wins da Vinci Award for Compas™ Computerized Prosthesis Alignment System 3
(Date:9/30/2014)... By Kathleen Doheny ... (HealthDay News) -- Children who are given broad-spectrum antibiotics ... higher risk of becoming obese during childhood, new research ... organisms than narrow-spectrum ones, according to the study. ... need antibiotics, and which antibiotic you are picking," said ...
(Date:9/30/2014)... VA (PRWEB) September 30, 2014 Visit ... of Chestnut Hill and you will find a loving ... together, Amyotrophic Lateral Sclerosis. , Steve was ... or Lou Gehrig’s Disease – just before the couple’s ... primary caregiver. , A new video, “Care, Support ...
(Date:9/30/2014)... September 30, 2014 TrailMyx.com —the ... October Flavor of the Month: raw pumpkin seeds. , ... of squash”)—are rich in protein, and valued by experts ... multiple types of vitamin E. They are prized for ... and proper bowel function. , Of course, pumpkin seeds ...
(Date:9/30/2014)... 30, 2014 Thanks to ... National Children’s Oral Health Foundation: America’s ToothFairy® ... to non-profit clinical partners. These organizations are ... deliver comprehensive educational, preventive and treatment services ...     Just Kids Dental: $25,000 ...
(Date:9/30/2014)... 30, 2014 (HealthDay News) -- In books and movies, plots ... Now, new research suggests that the stereotype may ... looked at data on more than 12,000 people from Finland. ... in Turku, Finland, found that women typically preferred men who ... consistent throughout their lives. On the other hand, men ...
Breaking Medicine News(10 mins):Health News:Antibiotic Use Before Age 2 Might Raise Obesity Risk, Study Says 2Health News:Antibiotic Use Before Age 2 Might Raise Obesity Risk, Study Says 3Health News:Hospice Provides Care and Support to Patients and Family Caregivers with ALS 2Health News:TrailMyx.com Features October Flavor of the Month 2Health News:America's ToothFairy Awards More Than $150,000 in Grants to Save Young Smiles 2Health News:America's ToothFairy Awards More Than $150,000 in Grants to Save Young Smiles 3Health News:When It Comes to Sex Partners, Men Prefer Younger Women: Study 2
... ALEXANDRIA, Va., Aug. 8 /PRNewswire-USNewswire/ National Hospice and,Palliative ... of the 2008 Circle of Life Award(R). This ... programs that,demonstrate superior vision, depth, and scope., ... American Hospital,Association,s annual summit in San Diego. This ...
... levels of testosterone may be a key factor in ... could help explain why males in a population are ... Previous research has linked testosterone, the male sex hormone, ... compared to females, experience more bouts of disease, and ...
... Children,s Hospital & Research Center Oakland continues to lead ... a new medical journal focused on children and teenagers. ... Pediatric Rehabilitation Department, is the founder and editor-in-chief of ... Approach . The quarterly journal released its second issue ...
... Eastern Insurance,Holdings, Inc. (Nasdaq: EIHI ... has executed a definitive agreement to acquire ... a transaction valued at,approximately $14.9 million, including ... wholly owned subsidiary is Employers Security Insurance,Company, ...
... of victims get to hospital quickly enough to limit damage, ... people who have strokes don,t act quickly enough to get ... study finds. , "One of the problems is that a ... stroke," said Kathryn M. Rose, a research associate professor of ...
... Aug. 7 Vapotherm, the,global leader in High ... the Food and Drug Administration (FDA) for Precision,Flow(TM), ... gas,blending, flow control and humidification technology into one ... gases., Other Vapotherm products are currently used ...
Cached Medicine News:Health News:Circle of Life Awards Recognize Innovative End-of-Life Care Providers 2Health News:Circle of Life Awards Recognize Innovative End-of-Life Care Providers 3Health News:Testosterone key to disease transmission 2Health News:Children's Hospital Oakland publishes first of its kind pediatric rehabilitation journal 2Health News:Eastern Insurance Holdings, Inc. Announces Definitive Agreement to Acquire Employers Security Holding Company and Subsidiaries 2Health News:Eastern Insurance Holdings, Inc. Announces Definitive Agreement to Acquire Employers Security Holding Company and Subsidiaries 3Health News:Eastern Insurance Holdings, Inc. Announces Definitive Agreement to Acquire Employers Security Holding Company and Subsidiaries 4Health News:Many Miss Out on Stroke Treatment 2Health News:Many Miss Out on Stroke Treatment 3Health News:Vapotherm(R) Precision Flow(TM) Receives FDA 510(k) Clearance 2
... Model V-1000 is a new addition to the ... This high performance pump can achieve an ultimate ... of 64 L/min. Applications For ... concentrators Distillation applications from lab size ...
... deliver critical performance for all vacuum requirements. ... pump performance to suit all applications. The ... checking of proper oil levels at a ... designed to work with all Thermo Savant ...
... The OFP400 Oil-free Vacuum Pump is designed for ... high chemical resistance, quiet running and eliminates oil ... any oil to operate. Less mess, less fuss., ... 4-headed design with chemically resistant solid ETFE and ...
... several different two-stage, oil-sealed, rotary vane vacuum ... applications. Each pump comes complete with a ... and Oil Mist Filter (EMF-10). The GBORK ... ballast to keep the oil clean without ...
Medicine Products: